Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Pisansky

Pain Medicine Maple Grove, MN Medical Doctor

NPI 1730562364 CMS profile 4224973

12000 Elm Creek Blvd N Ste 300, Maple Grove, MN 55369

Open in the dashboard

General payments

$19,009

194 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Pisansky of Maple Grove, MN is reported in the CMS Open Payments database as having received $19,009 across 194 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,813 24
2024 General $5,304 60
2023 General $6,823 67
2022 General $193 3
2020 General $1,362 14
2019 General $2,515 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Pisansky
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Andrew Pisansky were reported at $2,813. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Andrew Pisansky Pain Medicine median Middle half National median
2019 $2,515 $498 $126–$1,682 $163
2020 $1,362 $284 $80–$910 $114
2021 $0 $399 $112–$1,219 $132
2022 $193 $455 $137–$1,484 $149
2023 $6,823 $484 $128–$1,495 $160
2024 $5,304 $498 $131–$1,540 $164
2025 $2,813 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $6,895 74 payments
  2. Boston Scientific Corporation $3,088 23 payments
  3. Abbott Laboratories $1,628 18 payments
  4. Nevro Corp. $1,594 21 payments
  5. SI-BONE, Inc. $1,536 11 payments
  6. Spinal Simplicity, LLC $1,165 7 payments
  7. Relievant Medsystems, Inc. $1,045 11 payments
  8. SPR Therapeutics, Inc $846 10 payments
  9. Vertos Medical, Inc. $563 6 payments
  10. Medtronic USA, Inc. $542 10 payments
  11. Other $107 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $10,391 58 payments
  2. Food and Beverage $8,130 134 payments
  3. Education $488 2 payments
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $2,520 31 payments
  2. KYPHON EXPRESS II KYPHOPAK TRAY $1,961 12 payments
  3. SYNCHROMEDII $1,678 23 payments
  4. Senza Spinal Cord Stimulation System $1,529 19 payments
  5. IFUSE IMPLANT SYSTEM $1,296 5 payments
  6. HA MINUTEMAN G3-R $1,165 7 payments
  7. Intracept Pain $1,045 11 payments
  8. Intracept Pain $1,045 11 payments
  9. Intracept Pain $1,045 11 payments
  10. Intracept Pain $1,045 11 payments
  11. Other $6,997 72 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

251

Median for Anesthesiology: 322

Drug cost

$3,517

Median for Anesthesiology: $8,738

Branded share of claims

21.5%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 27 $638
Methocarbamol Generic 35 $479
Pregabalin Generic 40 $463
Gabapentin Generic 32 $400
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 27 $361
Oxycodone Hcl Generic 13 $329
Cephalexin Generic 18 $319
Memantine Hcl Generic 17 $271
Tizanidine Hcl Generic 23 $191
Tramadol Hcl Generic 19 $67

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$107,739

Of which drugs: $4,105

Medicare patients

335

Average age 66

Services billed

1,718

230 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 64%
Depression 49%
Diabetes 31%
Ischemic heart disease 21%
Chronic kidney disease 21%
Osteoporosis 17%
Heart failure 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 30 184 $1,027

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

194 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record